|Bid||59.78 x 800|
|Ask||59.81 x 800|
|Day's Range||59.66 - 60.29|
|52 Week Range||59.66 - 85.97|
|Beta (5Y Monthly)||0.57|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||2.72 (4.49%)|
|Ex-Dividend Date||Sep 14, 2020|
|1y Target Est||N/A|
The healthcare is expected to witness substantial earnings growth of 5.1% in the third quarter, representing the second strongest sector this earnings season.
Citigroup analyst Mohit Bansal rates Gilead stock at Buy but lowered his target price to $75 from $80. He sees two more years of revenue decline.
The death of a clinical trial participant overshadowed clear signs of efficacy for the company's off-the-shelf cellular therapy for non-Hodgkin lymphoma.